Open an account

Exscientia

EXAI · NASDAQ

Price unavailable right now.

No price history for this range.

About EXAI

Exscientia Plc engages in the application of artificial intelligence (AI) and machine learning (ML) to the discovery and design of therapeutic compounds. The company is headquartered in Oxford, Oxfordshire and currently employs 483 full-time employees. The firm combines precision design with integrated experimentation to invent and develop drugs. The company uses artificial intelligence (AI) in drug discovery to progress AI-designed small molecules into a clinical setting. The company uses the patient's tissue data to define optimal profiles for research, improve experimental assessment during design and improve outcomes in a medical setting. The company has developed an internal pipeline focused on oncology, while its partnered pipeline extends to various other therapeutic areas. The company combines genetic data and global literature in machine learning models to anticipate and confirm disease-target associations. The firm's experimental platform records responses in real patient samples allowing it to generate high-precision views of potential patient response. Its product pipeline consists of GTAEXS617, EXS4318, EXS74539, and EXS73565.

Employees
483
Headquarters
Oxford, Oxfordshire
Listed
Oct 1, 2021
Sector
Health Care
Industry
Biotechnology
Website
exscientia.com

EXAI key statistics

This section is temporarily unavailable. Refresh to try again.

EXAI earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 21.3% on average.

  1. Q3 FY22: reported -$0.32 per share against an estimate of -$0.3256
  2. Q4 FY22: reported -$0.38 per share against an estimate of -$0.3313
  3. Q1 FY23: reported -$0.38 per share against an estimate of -$0.3604
  4. Q2 FY23: reported -$0.29 per share against an estimate of -$0.4164
  5. Q3 FY23: reported -$0.31 per share against an estimate of -$0.4164
  6. Q4 FY23: reported -$0.42 per share against an estimate of -$0.3506
  7. Q1 FY24: reported -$0.21 per share against an estimate of -$0.2898
  8. Q2 FY24: reported -$0.36 per share against an estimate of -$0.1138

EXAI news

  • Press releaseBusiness Wire

    Exscientia Achieves Milestones for Two Programmes in Sanofi Collaboration

  • Press releaseBusiness Wire

    Exscientia to Present New Preclinical Data for AI-designed LSD1 and MALT1 Inhibitors at ENA 2024

  • Press releaseBusiness Wire

    Data Demonstrating ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia Presented at the American Society for Bone and Mineral Research 2024 Annual Meeting

  • Press releasePRNewswire

    AI Revolution in Healthcare Gains Momentum as FDA Prepares for Tech Boom

  • Press releaseBusiness Wire

    Exscientia to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

  • Press releaseBusiness Wire

    Exscientia Business Update for Second Quarter and First Half 2024

  • Press releaseGlobe Newswire

    How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates

  • Vandana Singh

    AI-Powered Drug Discovery Firm Exscientia To Merge With Nvidia-Partner Recursion Pharmaceuticals

Similar companies

Companies in the same industry as Exscientia

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.